AVI Names New CEO

Xconomy Seattle — 

AVI Biopharma, the Bothell, WA-based developer of RNA-based therapies, said today it has hired Chris Garabedian as its new president and CEO. Garabedian, 44, previously was a vice president of corporate development with Summit, NJ-based Celgene (NASDAQ: CELG). AVI has had an opening for a permanent CEO since April, when Les Hudson was ousted in a shareholder uprising. Garabedian starts on January 1, and will replace AVI interim president and CEO David Boyle, who will continue with the company as chief financial officer and senior vice president.